Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Nivolumab and Bevacizumab in Patients With Advanced and or Metastatic Hepatocellular Carcinoma (NUANCE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03382886
Recruitment Status : Active, not recruiting
First Posted : December 26, 2017
Last Update Posted : June 26, 2019
Sponsor:
Collaborator:
Bristol-Myers Squibb
Information provided by (Responsible Party):
University of Utah

Brief Summary:
This is an open label, phase I study to test for maximum tolerated dose (MTD) or recommended phase II dose (RP2D) of the combination of nivolumab and bevacizumab. The study will use a 3+3 phase I study design using a fixed dose of nivolumab (240mg) and escalating doses of bevacizumab (1-10mg).

Condition or disease Intervention/treatment Phase
Hepatocellular Carcinoma Drug: Nivolumab Drug: Bevacizumab Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 12 participants
Intervention Model: Single Group Assignment
Intervention Model Description: This is an open label, phase I study to test for maximum tolerated dose (MTD) or recommended phase II dose (RP2D)
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase I Open Label Trial of a Combination of Nivolumab and Bevacizumab in Patients With Advanced and or Metastatic Hepatocellular Carcinoma
Actual Study Start Date : April 11, 2018
Estimated Primary Completion Date : March 2023
Estimated Study Completion Date : March 2023

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Nivolumab and bevacizumab, all patients Drug: Nivolumab

Nivolumab will be administered as a 240mg IV infusion given once every two weeks (+/- 3 days).

Subjects will remain on study treatment for up to two years or until progression or excessive toxicity

Other Name: OPDIVO

Drug: Bevacizumab

Bevacizumab will be administered as an IV infusion from 1-10mg/kg in accordance with the appropriate subject cohort being examined as described below:

Dose level 1: 5 mg/kg intravenously once every two weeks Dose level 2: 10 mg/kg intravenously once every two weeks Dose level -1: 1 mg/kg intravenously once every two weeks

Dosing is based on actual body weight. There is no dose adjustment for obese or frail individuals. Dosing is recalculated if patient weight changes by more than 10% as reviewed by the principal investigator.

Subjects will remain on study treatment for up to two years or until progression or excessive toxicity





Primary Outcome Measures :
  1. Adverse Events that occur [ Time Frame: Every 14 day cycle for up to 2 years - Patients are expected to be on treatment for an average of 6 months ]

    Investigate the safety and tolerability of 14-day cycles of nivolumab plus bevacizumab.

    Adverse events will be collected for each subject that received the study treatment combination.


  2. Determine the maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D) [ Time Frame: The DLT period will begin at Cycle 1 Day 1 and continue through Cycle 1 Day 28 for each patient ]

    Determine the maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D).

    Dose Limiting Toxicities (DLT) will define subsequent subject accrual and dose escalation



Secondary Outcome Measures :
  1. Progression Free Survival (PFS) [ Time Frame: 3 years after treatment stops ]

    To examine the effect of the study treatment combination on the rate of progression-free survival (PFS).

    Subjects will have regular imaging scans to measure disease status and response will be defined by RECIST1.1.


  2. Overall Survival [ Time Frame: 3 years after treatment stops ]
    To examine the effect of the study treatment combination on the rate of overall survival.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Confirmed unresectable or metastatic hepatocellular carcinoma. Confirmation either by histologic confirmation or accepted radiographic criteria.
  • Received at least one line of therapy with a TKI (including, but not limited to sorafenib, lenvatinib, and/or regorafenib) with evidence of disease progression clinically or radiographically as deemed by investigator, or refused therapy with a TKI. No more than two lines of prior therapy are allowed.
  • Measurable disease per RECIST1.1.
  • Age ≥18 years.
  • ECOG performance status of 0 to 1.
  • Life expectancy ≥ 12 weeks.
  • Childs Pugh A (5-6 points). Demonstrate adequate organ function as defined in the table below

Hematologic:

Absolute neutrophil count (ANC) ≥ 1.5 k/µL. Platelets ≥ 100 k/µL Hemoglobin ≥ 9 g/dL

Renal:

Creatinine < 2 × ULN OR

- Able to provide informed consent and willing to sign an approved consent form that conforms to federal and institutional guidelines.

Exclusion Criteria:

  • Prior treatment with anti-PD1 or anti-PD-L1 antibody therapy.
  • Subjects with a prior history of DVT/PE, who have not been on stable doses of anticoagulation with low molecular weight heparin or oral anticoagulant for at least two weeks.
  • History of arterial thromboembolic event in past 6 months (including CVA, MI).
  • Systemic anti-cancer treatment within 2 weeks, all ongoing adverse events related to previous systemic anti-cancer therapy resolved to grade ≤1.
  • Radiotherapy within 2 weeks of first dose of study medications.
  • Major surgery within 6 weeks of first dose of study medications. Minor procedures (e.g. port placement, endoscopy with intervention) within 4 weeks of first dose of study medications.
  • Presence of ≥ CTCAE grade 2 toxicity due to prior cancer therapy (except alopecia, peripheral neuropathy which are excluded if ≥ CTCAE grade 3).
  • Medical condition that requires chronic systemic steroid therapy, or any other form of immunosuppressive medication.
  • Active ongoing infection requiring therapy.
  • Active HIV infection.
  • History of severe hypersensitivity reaction to another monoclonal antibody.
  • Active central nervous system metastases and/or carcinomatous meningitis (stable treated brain metastases not requiring steroids >4 weeks allowed).
  • Cardiac conditions: class 3-4 New York Heart Association congestive heart failure, known baseline LVEF < 50%, transmural myocardial infarction, uncontrolled hypertension, angina pectoris requiring medication, clinically significant valvular disease, high-risk arrhythmia in the past 12 months.
  • Any history of autoimmune disease requiring treatment in the past 5 years or felt to be at risk to reactivate autoimmune disease. Patients who are felt to no longer be at risk of activating a known autoimmune disease (e.g. type 1 diabetes, ulcerative colitis s/p complete colectomy, autoimmune thyroiditis s/p thyroidectomy or medical ablation, etc.) may be allowed to participate after discussion with the PI
  • Pregnant, breast feeding, or planning to become pregnant.
  • Women of childbearing potential (WOCBP) must agree to follow instructions for method(s) of contraception for the duration of study treatment with nivolumab and 5 months after the last dose of study treatment i.e., 30 days (duration of ovulatory cycle) plus the time required for the investigational drug to undergo approximately five half-lives. Contraception as described in section 7.3
  • Males who are sexually active with WOCBP must agree to follow instructions for method(s) of contraception for the duration of study treatment with nivolumab and 7 months after the last dose of study treatment i.e., 90 days (duration of sperm turnover) plus the time required for the investigational drug to undergo approximately five half-lives. Contraception as described in section 7.3
  • Received any live vaccine within the last 30 days.
  • Other malignancy requiring treatment in the prior 2 years with the exception of locally treated squamous or basal cell carcinoma.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03382886


Locations
Layout table for location information
United States, Utah
Huntsman Cancer Institute
Salt Lake City, Utah, United States, 84112
Sponsors and Collaborators
University of Utah
Bristol-Myers Squibb
Investigators
Layout table for investigator information
Principal Investigator: Glynn W Gilcrease, MD University of Utah

Layout table for additonal information
Responsible Party: University of Utah
ClinicalTrials.gov Identifier: NCT03382886     History of Changes
Other Study ID Numbers: HCI103945
First Posted: December 26, 2017    Key Record Dates
Last Update Posted: June 26, 2019
Last Verified: June 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by University of Utah:
Advanced and/or metastatic

Additional relevant MeSH terms:
Layout table for MeSH terms
Carcinoma
Carcinoma, Hepatocellular
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms
Adenocarcinoma
Liver Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Digestive System Diseases
Liver Diseases
Bevacizumab
Nivolumab
Antineoplastic Agents, Immunological
Antineoplastic Agents
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Physiological Effects of Drugs
Growth Inhibitors